| For the Three Months Ended March 31, | ||||||||||||||||||||||||||||||||||||
| 2024 | 2023 | 2019 Equity Incentive Plan - Share Options | 10,607,005 | 13,118,656 | 2019 Equity Incentive Plan - RSUs | 620,800 | 2,110,222 | Conditional Share Capital Plan - RSUs | 5,385,591 | — | Outstanding warrants | 4,940,135 | 4,940,135 | 21,553,531 | 20,169,013 | |||||||||||||||||||||
| Performance Goals | | | Weighting | | | Actual | | | Achieved |
| Zynlonta Revenue and Advance Clinical Trials | | | 40% (25% revenue) | | | • Achieved $69.1 million in net sales • LOTIS 7: Initiated trial and cleared first dosing cohort with no DLT • LOTIS 5: Progressed the trial and accelerated subject enrollment in 2023 | | | 24% |
| | | | | | | ||||
| Advance PBD-Based Pipeline on Solid Tumor | | | 25% | | | • ADCT-601: Advanced trial; reached MTD and currently in dose optimization | | | 25% |
| Name and Principal Position | | | Year | | | Salary | | | Bonus(1) | | | Stock Awards(2) | | | Option Awards(3) | | | Non-Equity Incentive Plan Compensation | | | Non- Qualified Deferred Compensation Earnings | | | All Other Compensation(4) | | | Total |
| Ameet Mallik Chief Executive Officer | | | 2023 | | | $721,000 | | | $705,065 | | | $1,059,300 | | | $881,250 | | | $367,710 | | | $— | | | $45,100 | | | $3,779,425 |
| Jose “Pepe” Carmona Chief Financial Officer | | | 2023 | | | $480,000 | | | $180,000 | | | $374,500 | | | $— | | | $204,000 | | | $— | | | $20,857 | | | $1,259,357 |
| Mohamed Zaki(5) Chief Medical Officer | | | 2023 | | | $647,292 | | | $1,475,000 | | | $288,900 | | | $1,701,000 | | | $276,250 | | | $— | | | $15,409 | | | $4,403,851 |
